Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP001379

Drug Information
Synonyms51-45-6; KBio2_001325; Istamina [Italian]; Istamina; Bio1_001465; 2-Imidazol-4-ylethylamine; .beta.-Imidazolyl-4-ethylamine; Ergotidine; NCGC00015513-01; Lopac0_000595; NCGC00093371-04; Imidazole-4-ethylamine; 2-(1H-imidazol-4-yl)ethan-1-amine; Spectrum5_000796; C00388; SMP1_000151; MLS000069447; KBio2_003025; CHEMBL90; UNII-820484N8I3; STK346752; D08040; 1H-Imidazole-4-ethanamine; NCGC00015513-08; STOCK5S-55669; Ethylamine, 2-imidazol-4-yl-; BSPBio_002124; IDI1_002144; EINECS 200-100-6; KBioGR_001580; Spectrum3_000452; [3H]histamine; AC-13185; 1avn; Spectrum_000845; NINDS_000308; HSDB 3338; KBio1_000308; Spectrum4_000960; NCGC00093371-03; BSPBio_001117; bmse000744; HMS1362G19; L-histamine; nchembio.87-comp54; HMS1990G19; KBio3_000854; 1qft; SDCCGMLS-0066601.P001; Bio1_000976; Bio2_000389; H7125_SIGMA; NSC 33792; histamine; 924364-91-0; AC1Q54BW; Eramin; KBio2_003893; Bio2_000869; KBioSS_000457; MolPort-001-785-597; Histaminum (TN); beta-Imidazolyl-4-ethylamine; 2-[4-Imidazolyl]ethylamine; KBioGR_000457; LS-75835; Imidazole, 4-(2-aminoethyl)-; nchembio714-comp1; AKOS000274386; KBio3_000853; NCGC00093371-05; beta-Aminoethylimidazole; CID774; 53290_FLUKA; CHEBI:18295; F411C768-A159-4FC0-A195-291A08BB03AA; MolPort-002-042-264; ALBB-005968; KBio2_005593; Histamine (DCF); KBio3_001344; Free histamine; Ergamine; ZERO/004089; 5-Imidazoleethylamine; BCBcMAP01_000250; KBioSS_001325; Histamine, Free Base; beta-Aminoethylglyoxaline; 4-Imidazoleethylamine; HMS1792G19; KBio2_000457; IDI1_000308; 2-(1H-Imidazol-4-yl)ethanamine; Histaminum; 2-(4-Imidazolyl)ethylamine; Lopac-H-7250; CCRIS 6535; 2-(1H-imidazol-5-yl)ethanamine; Histamine Base; NSC33792; Spectrum2_000665; SPBio_000729; Theramine; ST073926; NCGC00093371-02; DivK1c_000308; 64422-25-9; AC1Q54BV; Bio1_000487; L000292; WLN: T5M CNJ D2Z; 1H-Imidazole-5-ethanamine; 4-(2-Aminoethyl)-1H-imidazole; beta-aminothethylglyoxaline; SMR000059091; AC1L19ZT; Histamine [USAN]; KBio2_006461; 2-(3H-Imidazol-4-yl)-ethylamine    
IndicationRespiratory allergiesApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnti-Allergic Agents    
CAS NumberCAS 75614-87-8
PubChem Compound IDCID 774.    
PubChem Substance IDSID 3678.    
TargetHistamine H1 receptorAgonist[1]
Ref 1Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543